Bicara Therapeutics has raised $315 million in an IPO to fund a pivotal study for a therapy targeting head and neck squamous cell carcinoma. The therapy, ficerafusp alfa, is designed to hit two cancer targets and is being tested in combination with the immunotherapy Keytruda. Bicara aims to overcome resistance to immunotherapies in HPV-negative HNSCC cases and sees potential in other solid tumors as well. Zenas Biopharma raised $225 million for a drug targeting B cells in autoimmune disorders, while MBX Biosciences raised $163 million for longer-acting peptide drugs targeting hormone deficiencies. Both companies plan to advance their drug candidates through clinical trials.
Source link
3 Biotech IPOs, $703M Raised for Clinical Trials in Cancer, Immunology & Endocrine Disorders
